MBX Biosciences, Inc. (NYSE:MBX) Director Purchases $1,551,962.80 in Stock

MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon purchased 143,170 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were acquired at an average cost of $10.84 per share, for a total transaction of $1,551,962.80. Following the purchase, the director now owns 3,255,000 shares of the company’s stock, valued at $35,284,200. This represents a 4.60 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MBX Biosciences Trading Up 2.9 %

Shares of NYSE MBX traded up $0.32 during mid-day trading on Wednesday, hitting $11.22. 120,827 shares of the company’s stock traded hands, compared to its average volume of 319,826. MBX Biosciences, Inc. has a 1 year low of $8.63 and a 1 year high of $27.50. The business has a 50-day moving average of $14.22.

Institutional Investors Weigh In On MBX Biosciences

Several institutional investors have recently modified their holdings of MBX. Frazier Life Sciences Management L.P. purchased a new stake in MBX Biosciences during the 3rd quarter valued at $155,499,000. NEA Management Company LLC purchased a new stake in shares of MBX Biosciences in the third quarter valued at $93,904,000. Wellington Management Group LLP purchased a new position in shares of MBX Biosciences during the 3rd quarter worth about $74,261,000. RA Capital Management L.P. bought a new position in MBX Biosciences during the 3rd quarter valued at about $39,264,000. Finally, Driehaus Capital Management LLC raised its position in MBX Biosciences by 61.2% in the 4th quarter. Driehaus Capital Management LLC now owns 1,581,760 shares of the company’s stock worth $29,152,000 after purchasing an additional 600,438 shares during the period.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.